EYNEWAL
LIVE

Serial Number

79249987

Owner

NOVARTIS AG

Attorney

Maury M. Tepper, III

Filing Date

Dec 13, 2018

Add to watchlist:

No watchlists yet
View on USPTO

EYNEWAL Trademark

Serial Number: 79249987 • Registration: 5809598

EYNEWAL is a trademark filed by NOVARTIS AG on December 13, 2018. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

NOVARTIS AG (7,166 trademarks)

CH-4002
BASEL , CH

Entity Type: 03

Trademark Details

Filing Date

December 13, 2018

Registration Date

July 23, 2019

Published for Opposition

May 7, 2019

Cancellation Date

July 21, 2022

Goods & Services

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal pharmaceutical preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Filing History

NOTIFICATION PROCESSED BY IB
Dec 21, 2022 GPNX
NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Aug 7, 2022 DENC
DEATH OF INTERNATIONAL REGISTRATION
Aug 7, 2022 DETH
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 6, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 14, 2019 FICS
FINAL DISPOSITION PROCESSED
Nov 14, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 23, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 23, 2019 R.PR
PUBLISHED FOR OPPOSITION
May 7, 2019 PUBO
NOTICE OF PUBLICATION
Apr 17, 2019 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 22, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 20, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 19, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 19, 2019 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 18, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 18, 2019 REAP
REFUSAL PROCESSED BY IB
Mar 8, 2019 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 20, 2019 RFCS
REFUSAL PROCESSED BY MPU
Feb 20, 2019 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 7, 2019 RFCR
NON-FINAL ACTION WRITTEN
Feb 6, 2019 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Feb 6, 2019 ZZZX
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 6, 2019 CNSA
ASSIGNED TO EXAMINER
Feb 5, 2019 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 2, 2019 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 29, 2019 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jan 28, 2019 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 24, 2019 REPR